Related Experiment Videos
Aggressive oligodendroglioma: a chemosensitive tumor.
J G Cairncross1, D R Macdonald, D A Ramsay
1Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
Neurosurgery
|July 1, 1992
Summary
Aggressive oligodendrogliomas respond well to chemotherapy. A procarbazine, CCNU (lomustine), and vincristine (PCV) regimen showed effectiveness in most patients with newly diagnosed or recurrent tumors.
Area of Science:
- Neuro-oncology
- Cancer chemotherapy
- Oligodendroglioma research
Background:
- Aggressive oligodendrogliomas are malignant brain tumors.
- These tumors are often symptomatic, enlarging, and enhancing on imaging.
- Chemotherapy is a potential treatment modality for these gliomas.
Purpose of the Study:
- To evaluate the efficacy of chemotherapy in patients with aggressive oligodendrogliomas.
- To identify effective chemotherapeutic agents or combinations for this rare glioma.
Main Methods:
- Retrospective analysis of 19 consecutively treated patients.
- Treatment involved chemotherapy regimens, including procarbazine, CCNU (lomustine), and vincristine (PCV).
- Assessment of treatment response in newly diagnosed and recurrent cases.
Main Results:
- Chemotherapy demonstrated significant response rates in aggressive oligodendrogliomas.
- 18 out of 19 patients showed a response to treatment.
- The procarbazine, CCNU (lomustine), and vincristine (PCV) regimen was found to be predictably effective.
Conclusions:
- Chemotherapy is an effective treatment for aggressive oligodendrogliomas.
- The PCV regimen is a reliable option, but other drugs also show activity.
- Further cooperative group trials are needed to optimize drug selection and treatment strategies.